WELGENE Business Summary

Welgene Biotech Co., Ltd. (6661.TWO) operates a dual-revenue business model centered on high-complexity genomic services and the distribution of specialized life science instrumentation. The company's primary revenue driver is its Biotechnology Testing segment, which provides comprehensive genetic analysis services including Next-Generation Sequencing (NGS), DNA microarray analysis, and real-time quantitative PCR for clinical, academic, and industrial clients. Complementing this is its Equipment Trading segment, which monetizes the sale of medical instruments and laboratory reagents from global partners such as Agilent and Guardant Health. Within the Taiwan TPEx market, Welgene occupies a specialized niche in molecular diagnostics and genomic research, competing directly with local peers such as Abnova Taiwan Corp (4133), BioLASCO Taiwan Co Ltd (6662), and RBC Bioscience Corporation (6848). The company is led by a stable executive team with deep roots in Taiwan's biotechnology sector. Fu Chien Chen has served as both Chairman and Chief Executive Officer since the company's inception in 2003, providing over two decades of strategic continuity. The leadership team includes Director of Finance and CFO Ying Jen Chen, who has overseen the firm's fiscal operations since 2014, and Corporate Officer I Hsing Lin, a key principal since 2004. The Board of Directors is composed of industry veterans including Sheng-In Cheng and Hsiao Min Li. Notably, the company has attracted institutional interest from global investment firms, including Marathon Asset Management Limited, which maintained a significant minority stake as of early 2026.